Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 08 December 2016

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cost-effectiveness of treating chronic HCV in people who inject drugs

A study in this month's issue of the Journal of Gastroenterology & Hepatology assesses the cost-effectiveness of treating chronic hepatitis C virus in people who inject drugs in Australia.

News image

Dr Adam Visconti and colleagues evaluated the cost-effectiveness of hepatitis C virus treatment with pegylated interferon alfa-2a and ribavirin in current and former people who inject drugs.

A decision analytic model simulated the lifetime costs and outcomes of 4 treatment options, including early treatment with mild fibrosis, standard treatment with moderate fibrosis, late treatment with compensated cirrhosis, and no treatment.

The research team simulated treatment modalities across current, former, and never-injector cohorts of 1000 hypothetical patients with chronic hepatitis C virus.

The main outcome measures were incremental costs per quality-adjusted life years gained, and incremental cost-effectiveness ratios were calculated for each cohort.

The doctors noted that treatment of current people who inject drugs during mild fibrosis resulted in a discounted average gain of 1.60 quality-adjusted life years for an added cost of $12 723 compared with no treatment.

This yielded an incremental cost-effectiveness ratios of $7941 per quality-adjusted life years gained.

Early treatment was more cost-effective
Journal of Gastroenterology and Hepatology

Former people who inject drugs gained 1.80 quality-adjusted life years for $10 441 for early treatment compared with no treatment, resulting in an incremental cost-effectiveness ratios of $5808 per quality-adjusted life years gained.

The research team found that never-injectors gained 2.3 quality-adjusted life years for $9290 compared with no treatment—an incremental cost-effectiveness ratios of $3985 per quality-adjusted life years gained.

Early treatment was more cost-effective than late treatment in all cohorts.

Dr Visconti's team commented "Despite comorbidities, increased mortality, and reduced adherence, treatment of both current and former people who inject drugs is cost-effective."

"Our estimates fall below the unofficial Australian cost-effectiveness threshold of $AUD 50 000 per quality-adjusted life years for public subsidies."

"Scaling up treatment for people who inject drugs can be justified on purely economic grounds."

J Gastroenterol Hepatol 2013: 28(4): 707-716
18 April 2013

Go to top of page Email this page Email this page to a colleague

 08 December 2016 
Intestinal tuberculosis vs Crohn's disease
 08 December 2016 
Precision medicine in IBD
 08 December 2016 
Preterm birth in women with IBD
 07 December 2016 
Iron deficiency in ulcerative colitis
 07 December 2016 
IBD source of information and patient education
 07 December 2016 
End-of-rotation resident transition and in-hospital mortality
 06 December 2016 
Anti-TNF therapy for IBD
 06 December 2016 
Crohn's disease and thyroid cancer risk
 06 December 2016 
IBD Disability Index in restorative proctocolectomy
 05 December 2016 
Reducing hospitalization in IBD
 05 December 2016 
Disease mangement in IBD
 05 December 2016 
New biomarkers for IBD diagnosis
 02 December 2016 
Hep E in acute liver failure
 02 December 2016 
Occurrence and severity of alcoholic hepatitis
 02 December 2016 
Food antigen in active eosinophilic esophagitis
 01 December 2016 
Iron deficiency in anemic ulcerative colitis patients
 01 December 2016 
Prognostic factors after paracetamol-induced liver failure
 01 December 2016 
Factors that influence colorectal cancer screening findings
 30 November 2016 
Certolizumab pegol in Crohn's disease
 30 November 2016 
Genetic risk of Crohn's in chronic granulomatous disease
 30 November 2016 
Rifaximin in diarrhea-predominant IBS
 29 November 2016 
Assessing liver steatosis
 29 November 2016 
Colorectal cancer surveillance in ulcerative colitis
 29 November 2016 
Treating Zenker's diverticulum
 28 November 2016 
Complications in celiac disease
 28 November 2016 
Monitoring IBD with mobile technology
 28 November 2016 
Reducing warfarin-related upper GI bleeds
 25 November 2016 
Metal vs plastic stents for pancreatic cancer surgery
 25 November 2016 
Yoga and IBS therapy 
 25 November 2016 
Colorectal cancer screening issues
 24 November 2016 
Partner burden in celiac disease
 24 November 2016 
Fusobacterium nucleatum for colorectal cancer prognosis
 24 November 2016 
PPIS and gastric cancer risk
 23 November 2016 
Quality assurance standards for colonoscopy
 23 November 2016 
Diagnosing autoimmune pancreatitis
 23 November 2016 
Readmissions in cirrhosis
 22 November 2016 
Bile acid diarrhea in function bowel disorder with diarrhea
 22 November 2016 
Fatigue in IBD
 22 November 2016 
PPIs and C. diff in ICU 
 21 November 2016 
Pain after endoscopic resection of gastric tumors
 21 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 21 November 2016 
Financial incentives and colorectal cancer screening
 18 November 2016 
Colorectal cancer risk and self-reported family history
 18 November 2016 
Ustekinumab in Crohn’s disease
 18 November 2016 
Antivirals and chemotherapy in Hep C patients with cancer
 17 November 2016 
Liver-related specialty care in patients with Hep C
 17 November 2016 
Risk of overweight in infants
 17 November 2016 
Moderate alcohol consumption and NAFLD
 16 November 2016 
PPI therapy in liver disease
 16 November 2016 
Education in Gastroenterology fellowship
 16 November 2016 
Paternal preconceptional use of anti-TNF-α agents
 15 November 2016 
Novel treatment of NASH 
 15 November 2016 
Contraceptives and ulcerative colitis
 15 November 2016 
Physician perspectives on Hep C management
 14 November 2016 
Cardiovascular risk in NAFLD 
 14 November 2016 
Vit D and NAFLD
 14 November 2016 
Malignancy risk in IBD 
 11 November 2016 
Treatment of Hep C along with opioid agonist therapy
 11 November 2016 
Diabetes and liver cancer risk in Hep C cirrhosis
 11 November 2016 
Biomarker of cirrhosis progression

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2016 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us